By John Meyer, consultant in business – Eurasia Business News, October 16, 2025. Article no. 1828
Adcytherix, a biopharmaceutical company based in Marseille, France, recently raised €30 million in seed funding to develop its next-generation antibody-drug conjugates (ADCs) for cancer treatment. Founded by Jack Elands and supported by Pontifax Venture Capital, the funding round was also backed by major life science investors including Pureos Bioventures, RA Capital Management, and Dawn Biopharma, a KKR-controlled platform. The company’s leadership team includes experienced experts in ADC development, aiming to address high unmet medical needs in oncology.
Read also : Gold : Build Your Wealth and Freedom
The €30 million funding is intended to advance the development of novel ADCs, building on the founding team’s prior success selling Emergence Therapeutics to Eli Lilly. Adcytherix’s mission is to establish itself as a distinct and innovative player in the ADC field, focusing on highly targeted cancer therapies that maximize efficacy while minimizing side effects. The seed funding reflects strong investor confidence in the company’s approach and leadership, supporting its goal to create breakthrough cancer treatments.
Our community already has 170,000 readers, joins us !
Subscribe to our Telegram channel
Follow us on Telegram, Facebook and Twitter
© Copyright 2025 – Eurasia Business News. Article no. 1828
Eurasia Business News 